[89Zr]Zr- BI-765063(Boehringer Ingelheim)

N/A

Report date: 2026/03/23 20:03:44

Base Information

Drug Name[89Zr]Zr- BI-765063(Boehringer Ingelheim)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Nuclides > Zirconium > 89Zr +[5]

Mechanisms of ActionSignal-regulatory protein alpha inhibitors

TargetsSignal-regulatory protein alpha

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and NeckMelanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlands

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesBoehringer Ingelheim Corp

China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. Kg

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and NeckMelanoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A